ERBB2 and metastatic neoplasm: As of note, our data were analyzed in an era prior to the regular use of treatments such as new generation HER2-directed therapies (fam-trastuzumab deruxtecan-nxki; ENHERTU) for HER2-positive metastatic disease, and before the use of olaparib (Lynparza) as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have been treated with chemotherapy before or after surgery.